$3.59 Billion is the total value of HHLR ADVISORS, LTD.'s 30 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTGN | Exit | NEON THERAPEUTICS INC | $0 | – | -312,500 | -100.0% | -0.06% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS IN | $0 | – | -865,923 | -100.0% | -0.12% | – |
| YY | Exit | YY INC | $0 | – | -193,490 | -100.0% | -0.48% | – |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -131,300 | -100.0% | -0.76% | – |
| SNAP | Exit | SNAP INCcl a | $0 | – | -6,925,129 | -100.0% | -1.58% | – |
| KANG | Exit | IKANG HEALTHCARE GROUP INCsponsored adr | $0 | – | -2,922,834 | -100.0% | -2.47% | – |
| WUBA | Exit | 58 COM INCspon adr rep a | $0 | – | -1,484,641 | -100.0% | -3.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BEIGENE LTD | 20 | Q3 2023 | 26.0% |
| JD.COM INC | 20 | Q3 2023 | 13.1% |
| IQIYI INC | 20 | Q3 2023 | 12.3% |
| MONDELEZ INTL INC | 20 | Q3 2023 | 5.9% |
| KINIKSA PHARMACEUTICALS LTD | 20 | Q3 2023 | 1.6% |
| SOHU COM LTD | 20 | Q3 2023 | 0.6% |
| PINDUODUO INC | 19 | Q3 2023 | 16.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 2.3% |
| BRIDGEBIO PHARMA INC | 18 | Q3 2023 | 3.4% |
| MELCO RESORTS AND ENTMT LTD | 18 | Q1 2023 | 2.8% |
View HHLR ADVISORS, LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| I-Mab | June 30, 2023 | 15,891,211 | 8.3% |
| BeiGene, Ltd. | February 14, 2023 | 147,043,058 | 10.9% |
| Gossamer Bio, Inc. | February 14, 2023 | 4,974,041 | 5.3% |
| On Holding AG | February 14, 2023 | 5,468,504 | 1.9% |
| Root, Inc. | February 14, 2023 | 138,977 | 1.5% |
| Yatsen Holding Ltd | February 14, 2023 | 300,560,602 | 19.1% |
| iQIYI, Inc. | July 11, 2022 | 149,075,912 | 5.0% |
| Apellis Pharmaceuticals, Inc. | February 14, 2022 | ? | ? |
| Beam Therapeutics Inc. | February 14, 2022 | ? | ? |
| Futu Holdings Ltd | February 14, 2022 | 2 | - |
View HHLR ADVISORS, LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 4 | 2024-02-01 |
| 13F-HR | 2023-11-14 |
View HHLR ADVISORS, LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.